Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Endometrial Neoplasms 1

Interventions

Cisplatin 18Brachytherapy 14Radiotherapy 11Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Radiation 7Paclitaxel 7aldesleukin 6Specimen Handling 6fludarabine phosphate 5fludarabine 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5Colposcopy 5Topotecan 4Immunoglobulin G 4Human Papillomavirus DNA Tests 4Fluorodeoxyglucose F18 4Disulfides 4Biopsy 4Bevacizumab 43-aminopyridine-2-carboxaldehyde thiosemicarbazone 4Trastuzumab 3Taxes 3Nivolumab 3Ipilimumab 3Congresses as Topic 3Carboplatin 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uterine Cervical Neoplasms × ferumoxtran-10 × Clear all
NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
384 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡